Full-Time

Executive – Or Senior

Director of Search & Evaluation, Oncology R&D, BD

Confirmed live in the last 24 hours

Deadline 6/18/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Senior, Expert

Cambridge, UK

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree with 10 plus years of experience in evaluating opportunities OR
  • Master’s degree with 8 plus years of experience OR
  • PhD degree with 5 plus years of experience
  • Strong R&D scientific and clinical background
  • Proven project and people leadership
  • Business and strategic acuity
  • Interpersonal skills
Responsibilities
  • Establish and drive the BD strategy for core strategic build areas within AZ Oncology, aligning with internal business partners and ensuring BD is embedded within the overall strategy
  • Coach and mentor Senior Director S&E team members, developing and embedding outstanding practices
  • Preparing and communicating Snr executive level reports of ongoing BD priorities
  • Point of contact and triage for Search and evaluation of external opportunities emanating from academia, VC, biotech and peer-pharma including early research projects, new modality platforms, clinical stage candidates and Life Cycle Management opportunities for our pipeline assets and franchises that can improve the scientific credibility of AZ’s Oncology R&D portfolio
  • Form and lead Cross-Functional Due Diligence teams and processes (for preclinical and early clinical assets) to drive detailed scientific evaluation of assets and deliver recommendations to governance bodies including the Senior Executive Management Team
  • Providing evaluation input and support for mid to late clinical Due Diligence assessments (with ongoing studies capable of achieving registration) when led from within the Business Development Operations DD team
  • Primary contact with the external partner throughout the deal process including during submission and negotiation of non-binding term sheet (NBTS) through to deal execution
  • Works collaboratively with the Transactional lead within the Oncology BD team during negotiation of any NBTS or definitive agreement
  • Leads the preparation and presentation of business case and other materials for senior management briefings with support from the R&D or BDO Transactions lead for transactional items
  • Representing Oncology R&D’s critical initiatives and business priorities with senior management of the external life sciences community
  • Best represents AstraZeneca’s scientific excellence through a deep understanding of the portfolio and ensures AZ is considered partner of choice
  • Deep specialised knowledge of industry trends in oncology including maintaining current awareness of competitor datasets in AZ areas of strategic focus
Desired Qualifications
  • Highly experienced and skilled deal maker with a broad and extensive track record
  • Recognised credibility with external companies, institutions and partners
  • PhD, M.D., or M.D./PhD in oncology or a related scientific field
  • Expert knowledge of commercial and financial evaluation and case preparation
  • Extensive deal experience and solid foundation of generally accepted BD practices
  • Strong scientific reputation in drug discovery and development
  • Ability to interact and communicate effectively with senior executive teams
  • History of building internal/external relationships, demonstrating cultural sensitivity and awareness
  • Extensive experience in pharmaceutical R&D, demonstrating international experience in multiple cultures and drug discovery / clinical environments
  • Ability to think critically, creatively and to anticipate and solve problems
  • Ability to navigate and be successful in a fast-paced, highly matrixed work environment

AstraZeneca develops and sells prescription medicines, focusing on Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are created through extensive research and development, followed by clinical trials and regulatory approvals. Unlike competitors, AstraZeneca emphasizes collaboration through its Open Innovation program and the A.Catalyst Network, which connects health innovation hubs worldwide. The company's goal is to advance healthcare by creating effective treatments for serious diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's partnership with Danaher enhances precision medicine diagnostics development.
  • The new Rockville cell therapy facility boosts AstraZeneca's manufacturing capabilities.
  • AstraZeneca's collaboration with CSPC expands its reach in the Chinese market.

What critics are saying

  • Increased competition in oncology could impact AstraZeneca's market share.
  • Biosimilars in cardiovascular and respiratory segments may pressure AstraZeneca's pricing.
  • Regulatory changes in the EU and China could delay AstraZeneca's clinical trials.

What makes AstraZeneca unique

  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • The company invests heavily in R&D to create new drugs and therapies.
  • AstraZeneca's Open Innovation program accelerates drug discovery through shared resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Jun 13th, 2025
Astrazeneca Enters Into Collaboration With Cspc

AstraZeneca enters into collaboration with CSPC

Cision
Jun 6th, 2025
Fixed-Duration Calquence Approved In Eu For 1L Cll

Fixed-duration Calquence approved in EU for 1L CLL

Business Weekly
Jun 5th, 2025
Sortera Bio secures £7.5m pre-seed funding

Sortera Bio, a Cambridge biotech, secured a £7.5m pre-seed round led by Cambridge Innovation Capital, with AstraZeneca and BioNTech participating. The funding will enhance Sortera's Deep Screening platform, which uses AI for drug discovery. Co-founded by Dr. Ben Porebski and Dr. Philipp Holliger, Sortera aims to deliver precision biologics. The technology was developed at the MRC Laboratory of Molecular Biology with AstraZeneca's support.

Pharmashots
Jun 2nd, 2025
AstraZeneca Presents P-III (MATTERHORN) Trial Data of Imfinzi as Perioperative Therapy for G/GEJ Cancers at ASCO 2025

AstraZeneca has shared P-III (MATTERHORN) trial data assessing perioperative Imfinzi + FLOT (n=474) vs PBO + FLOT (n=474) in 948 pts with stage II-IVA G/GEJ cancers at ASCO 2025

Cision
Jun 2nd, 2025
Block Listing Interim Review

2 June 2025 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris. (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 2 June 2025 Name of applicant: ASTRAZENECA PLC Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS -RELATED SHARE OPTION PLAN;